TX-FLUENCE
11.8.2022 14:32:09 CEST | Business Wire | Press release
Fluence Bioengineering, Inc. (Fluence), a leading global provider of energy-efficient LED lighting solutions for commercial cannabis and food production, in collaboration with REMY, a horticultural lighting provider to Israel’s growing agriculture industry, is supporting the record introduction of lighting technology solutions to Israel’s medical cannabis facilities.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220811005211/en/
Israel—considered a world leader in cannabis research, cultivation and advanced regulation—has positioned itself at the forefront of the $74 trillion global cannabis market through highly innovative technology and data applications. The country now boasts supply capabilities that surpass its domestic demand. As the Israeli market matures, more and more indoor farms are capitalizing on leading controlled environment agriculture strategies proven to optimize plant growth and profits.
REMY’s expertise, paired with Fluence’s products and evidence-based best practices for optimal lighting strategies at each phase of cannabis growth, has placed the companies’ collaborative designs in the three core categories of medical cannabis facilities in Israel: greenhouse, indoor and vertical farms.
Hybrid cultivation at Green Fields
Green Fields, which operates the largest medical cannabis growing facility in Israel, features a hybrid greenhouse model of harnessing sunlight and supplementing with artificial lighting to optimize plant quality. The forward-looking company chose Fluence and REMY to install a high-intensity lighting system.
"After working on several projects with REMY, we know the value of their professionalism, expertise and service. That's why we chose them for our flagship project," explained Jonathan Pisso, chief procurement officer of Green Fields. "The difference we saw in the first crop cycle using Fluence lighting was phenomenal. As a result of the facility's control system, we have a great deal of flexibility and maximum control. We have integrated all the technologies with an extremely powerful lighting system, which results in uniform growth and excellent results."
Growing indoors with Springs Valley Cannabis
Another popular type of cannabis facility in Israel is the fully indoor model, which allows control of all crop conditions to ensure uniform growth throughout the year while maximizing quality. Springs Valley Cannabis is setting up to become a major cannabis cultivator in Israel. It elected to use Fluence and REMY for lighting solutions in its indoor facility that covers an impressive 5,000 square meters of canopy.
"When we designed our unique facility, we sought trustworthy partners who would ensure our product would be a market leader. We found it in the combination of Fluence and REMY," said Yossi Shitrit, founder of Springs Valley Cannabis.
Trichome’s urban vertical farm
Located in the heart of an urban industrial area, Trichome operates a fully indoor, multi-tier vertical farming facility. Harnessing the power and control of indoor cultivation methods, Trichome searched for industry-leading partners with experience optimizing environmental parameters in a multi-tier environment. With Fluence’s SPYDR Series, Trichome leverages a high intensity, broad-spectrum strategy that delivers precise and uniform light to the plant canopy.
"Fluence’s and REMY's teams are extremely professional. They are dedicated to our success and bring us added value. The results are already exceeding our initial expectations," said Tony Levi, founder and CEO at Trichome. "It shows the potential for indoor growth in urban centers. The facility utilizes every square meter of the building for efficiency and uniformity."
"Israel is a technological 'playground' for the cannabis market, which makes it easy to examine and adopt advanced technologies quickly," said Timo Bongartz, general manager for Europe, the Middle East and Africa (EMEA) at Fluence. "With the early-adapter frame of mind that the Israeli industry practices, Fluence has managed to deliver expert horticulture knowledge and, together with REMY, cooperate with leading innovative growers to advance their operations."
In addition to providing lighting solutions, REMY specializes in the planning, installation, integration and quality assurance of large-scale agronomic solutions, as well as after-sales service and support.
"At the end of the day, the plant is the best indication for our success or failure—and we are achieving success in multiple, diverse cultivation environments," said Elad Toby, founder, CTO and chief business development officer for REMY.
To learn more about REMY, click here . To learn more about Fluence’s portfolio of luminaires and lighting controls, visit the company’s website here .
About Fluence
Fluence Bioengineering, Inc. (Fluence) creates powerful and energy-efficient LED lighting solutions for commercial crop production and research applications. Fluence is a leading LED lighting supplier in the global cannabis market and is committed to enabling more efficient crop production with the world’s top vertical farms and greenhouse produce growers. Fluence global headquarters are in Austin, Texas, with its EMEA headquarters in Rotterdam, Netherlands. Fluence operates as a business unit within Signify’s Digital Solutions division. For more information about Fluence, visit www.fluence.science .
About REMY
Established in 2008, REMY 108 LTD specializes in the planning, installation, integration and quality assurance of large-scale agronomic lighting solutions, as well as after-sales service and support, for commercial crop and food cultivation in Israel and beyond. REMY has been providing its customers with agronomic lighting since 2011 and it has been the company’s main focus since 2018. An authorized reseller of Fluence LED lighting solutions, it today also provides agronomic lighting training at its headquarters in Yanuv. For more information about REMY, visit https://www.remy.co.il/en/grow.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220811005211/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Vertex Presents New Data on ALYFTREK® at European Cystic Fibrosis Conference5.6.2026 18:00:00 CEST | Press release
- ALYFTREK Phase 3 data on children with cystic fibrosis ages 2 to 5 with vanzacaftor/tezacaftor/deutivacaftor-responsive genotypes including F/F and F/MF shows 65% reached sweat chloride levels of <30 mmol/L; Vertex on track to initiate global regulatory submissions in first half of 2026 - - Long-term 96-week interim analyses from two open-label extension studies demonstrate positive safety and efficacy profile of ALYFTREK in people with cystic fibrosis ages 6 and older -- Phase 3 data on TRIKAFTA® in children 1 to <2 years also presented; Vertex has initiated global regulatory submissions - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data demonstrating the potentially transformative impact of treating cystic fibrosis (CF) with ALYFTREK ® (vanzacaftor/tezacaftor/deutivacaftor) in children ages 2 to 5, as well as data from 96-week interim analyses of two open-label extension studies of ALYFTREK in children 6 to 11 years and people 12 years and older demonstrating
Owkin to Build AI Agents as Part of a Multi-Year K Pro Collaboration with Sanofi5.6.2026 13:00:00 CEST | Press release
Owkin, the agentic AI company pioneering Biological Artificial Superintelligence to transform drug discovery and development, today announced a multi-year collaboration with Sanofi to co-develop next-generation biopharma agents, to be backed by a five-year license for K Pro, Owkin’s AI Scientist. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260605704506/en/ K Pro, Owkin's AI scientist for biology, powered by multimodal patient data for smarter biopharma decision making. Owkin and Sanofi have collaborated since 2021 through a €90 million strategic partnership focused on target identification in oncology and patient subgrouping. The collaboration was later expanded to include drug positioning for Sanofi’s immunology pipeline. This new collaboration represents the next evolution in the partnership. During the five-year collaboration, Owkin will lead the end-to-end development of novel AI-driven biopharma agents purpose-built
DFNS Rebrands as the Core Banking Platform for Digital Assets5.6.2026 12:41:00 CEST | Press release
DFNS today announced a rebrand, marking its evolution from a wallet infrastructure to the first core banking platform for digital assets. The company is introducing a new logo, website, and market position as fintechs and institutions move their products and operations onchain. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260603859127/en/ Banks, fintechs, asset managers, trading firms, payment providers, market infrastructures, and clearing houses have stopped asking how to "add crypto." They're asking how to run financial products, controls, workflows, and client services on blockchain rails, with the reliability expected of core infrastructure. Some are going further still, exploring whether the blockchain can serve as the ledger itself, where an account is an onchain object rather than a row in a database. Where IBANs, virtual accounts, and blockchain wallets converge into one governed financial account. “DFNS was built
Compass Pathways Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)5.6.2026 12:30:00 CEST | Press release
Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, announced today that Compass granted equity awards under the Compass Pathways plc 2026 Inducement Plan to seventeen newly hired non-executive employees. The equity awards were granted on June 1, 2026 and consisted of options to purchase an aggregate of 157,000 shares and restricted share units or, in the case of employees in the United Kingdom nominal cost options, covering an aggregate of 74,700 shares. The options have an exercise price per share equal to $14.19, the closing price of the Company’s American Depositary Shares on the Nasdaq Global Select Market on the grant date, and will vest over a four-year period with 25% vesting on the first anniversary of the date of the grant and the remaining 75% vesting in equal monthly installments over the three-year period thereafter, subject to each employee’s continued employment. The restrict
Renewable Electricity, Soft Wheat Flour From Regenerative Agriculture, Initiatives to Support Local Communities: Barilla Shares These and Other Projects in “Stories of Sustainability.”5.6.2026 10:00:00 CEST | Press release
Barilla continues to advance its commitment to tastier products with less sugar and salt;An investment of 30 million euros in 2025 to quadruple photovoltaic capacity across plants, as part of a €168 million five-year plan focused on energy efficiency, renewable energy and sustainable water management.Barilla continues to expand regenerative agriculture practices across its global value chain, with over 816,000 tons of raw materials sourced through the Barilla Sustainable Farming program.4,000 tons of products donated worldwide and €2 million allocated to social causes in 2025, supporting communities across Barilla’s global footprint through food donations and social initiatives. A slimmer Tagliatelle pack that saves 150 tons of cardboard and cuts transport-related CO₂ emissions by 20%1; ready-made sauce jars made with around 65% recycled glass; the progressive scaling of regenerative agriculture practices across Barilla’s value chain and initiatives supporting inclusion and equal oppor
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom